Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and NIH CRM Collaborate to Apply rAAV Genome Editing to Stem Cells

Published: Friday, October 05, 2012
Last Updated: Friday, October 05, 2012
Bookmark and Share
Collaboration aims to understand the effects of specific gene sequences on stem cell differentiation.

Horizon Discovery (Horizon) has announced that it has signed a technology access agreement with the U.S. National Institutes of Health Center for Regenerative Medicine (NIH CRM), through Horizon’s Centers of Excellence (CoE) program.

The agreement will enable the NIH CRM to apply Horizon’s GENESIS™ genome editing technology to engineer stem cells in order to create isogenic disease models with induced mutations and/or lineage markers.

These disease models will be used to help researchers understand the effects of specific genes and mutations as stem cells differentiate, as well as create lineage reporters for stem cell differentiation.

The NIH CRM was recently established through support from the NIH Common Fund to provide the infrastructure to support and accelerate the clinical translation of stem cell-based technologies, and to develop widely available resources to be used as standards in stem cell research.

The GENESIS technology harnesses rAAV vectors to perform accurate and efficient gene-editing functions in human cells, by switching on a natural high-fidelity DNA-repair mechanism called homologous recombination (HR).

When harnessed using rAAV gene-editing vectors, HR allows the precise alteration of any DNA sequence, permitting the accurate modeling of genetic diseases in human cells, including stem cells, in vitro.

The use of these models in oncology is well established, and has predicted patient responses to targeted therapies both during drug development and in the clinic.

By applying this technology to other scientific areas Horizon hopes to lead to the development of personalized medicines by advancing scientific research.

“Through our CoE program, we aim to work with world leading experts in their fields, so we are delighted to be working with the NIH CRM, a key centre for stem cell research,” said Dr Rob Howes, CoE Program Manager, Horizon Discovery.

Dr Howes continued, “This agreement builds on proof of concept work carried out by Horizon Scientific Advisory Board member and rAAV-mediated gene editing inventor, David Russell, demonstrating the ability of rAAV to gene target in ES cells, and extends the scope of the CoE program into stem cell research.”

Horizon’s CoE program encompasses academic and not-for-profit research groups or laboratories to which Horizon commits resources to provide training and open access to its proprietary rAAV-mediated human gene-editing platform, GENESIS™.

Horizon also recently launched an online support site, www.rAAVers.org, for scientists working with rAAV-mediated genome editing.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon, Centre for Process Innovation, & University of Manchester Awarded £1.67M Innovate UK Funding
Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform.
Wednesday, February 18, 2015
Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
Two year master services agreement signed with an initial work order for $500,000 to carry out drug combination screening and in vitro assay development.
Monday, February 02, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery Group plc Acquires Haplogen Genomics GmbH
Strategic acquisition of high-throughput functional genomics platform aims to drive product development, revenue growth and enable broader market penetration.
Thursday, January 08, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!